BILL · 2019–20 SESSION

SB 5371: Insulin drug prices

Protecting consumers and purchasers from excessive increases in insulin drug prices.

Summary

Requires insulin drug manufacturers to notify the Health Care Authority's Washington Prescription Drug Program (WPDP) when increasing the price of insulin by ten percent or more.
Requires the WPDP to determine if the price increase is excessive.
Allows the Attorney General's Office to take action against excessive price increases.

From the Senate Bill Report (Orig.) (SB 5371), written by the Legislature's nonpartisan staff. Read the full report ↗

Did not pass Did not pass · died in committee

AN ACT Relating to protecting consumers and purchasers from excessive increases in insulin drug prices;

No recorded floor votes. This measure never reached a floor vote.

Bill numbers restart every two years, so the same number is a different bill in each session.

SB 5371 (2025–26) Wine & spirit sales limits · Did not pass · stalled on the Senate floor
SB 5371 (2023–24) Orca vessel protection · Enacted with partial veto · Chapter 452, Laws of 2023
SB 5371 (2021–22) Sweetened beverage tax · Did not pass · died in committee
SB 5371 (2017–18) Public sector union finances · Did not pass · stalled on the Senate floor
SB 5371 (2015–16) Agency declaratory orders · Did not pass · stalled on the Senate floor
SB 5371 (2013–14) Devel. disabilities services · Did not pass · died in committee
SB 5371 (2011–12) Health insurance/under 19 · Enacted · Chapter 315, Laws of 2011
SB 5371 (2009–10) Parent-taught driver's edu · Did not pass · died in committee